Literature DB >> 21769100

Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response.

A Bacq1, L Balasse, G Biala, B Guiard, A M Gardier, A Schinkel, F Louis, V Vialou, M-P Martres, C Chevarin, M Hamon, B Giros, S Gautron.   

Abstract

High-affinity transporters for norepinephrine (NE) and serotonin (5-HT), which ensure neurotransmitter clearance at the synapse, are the principal targets of widely used antidepressant drugs. Antidepressants targeting these high-affinity transporters, however, do not provide positive treatment outcomes for all patients. Other monoamine transport systems, with lower affinity, have been detected in the brain, but their role is largely unknown. Here we report that OCT2, a member of the polyspecific organic cation transporter (OCT) family, is expressed notably in the limbic system and implicated in anxiety and depression-related behaviors in the mouse. Genetic deletion of OCT2 in mice produced a significant reduction in brain tissue concentrations of NE and 5-HT and in ex vivo uptake of both these neurotransmitters in the presence of the dual 5-HT-NE transport blocker, venlafaxine. In vivo clearance of NE and 5-HT evaluated using microiontophoretic electrophysiology was diminished in the hippocampus of OCT2(-/-) mice in the presence of venlafaxine, thereby affecting postsynaptic neuronal activity. OCT2(-/-) mice displayed an altered sensitivity to acute treatments with NE- and/or 5-HT-selective transport blockers in the forced-swim test. Moreover, the mutant mice were insensitive to long-term venlafaxine treatment in a more realistic, corticosterone-induced, chronic depression model. Our findings identify OCT2 as an important postsynaptic determinant of aminergic tonus and mood-related behaviors and a potential pharmacological target for mood disorders therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21769100     DOI: 10.1038/mp.2011.87

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  40 in total

Review 1.  Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.

Authors:  M A Daniels; C Kan; D M Willmes; K Ismail; F Pistrosch; D Hopkins; G Mingrone; S R Bornstein; A L Birkenfeld
Journal:  Pharmacogenomics J       Date:  2016-07-19       Impact factor: 3.550

2.  Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: uncovering novel targets to treat depression.

Authors:  Rebecca E Horton; Deana M Apple; W Anthony Owens; Nicole L Baganz; Sonia Cano; Nathan C Mitchell; Melissa Vitela; Georgianna G Gould; Wouter Koek; Lynette C Daws
Journal:  J Neurosci       Date:  2013-06-19       Impact factor: 6.167

3.  Antidepressant efficacy of a selective organic cation transporter blocker in a mouse model of depression.

Authors:  Alejandro Orrico-Sanchez; Laetitia Chausset-Boissarie; Rodolphe Alves de Sousa; Basile Coutens; Sara Rezai Amin; Vincent Vialou; Franck Louis; Assia Hessani; Patrick M Dansette; Teodoro Zornoza; Carole Gruszczynski; Bruno Giros; Bruno P Guiard; Francine Acher; Nicolas Pietrancosta; Sophie Gautron
Journal:  Mol Psychiatry       Date:  2019-10-16       Impact factor: 15.992

Review 4.  The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease.

Authors:  Sanjay K Nigam
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-01-06       Impact factor: 13.820

5.  Constitutive plasma membrane monoamine transporter (PMAT, Slc29a4) deficiency subtly affects anxiety-like and coping behaviours.

Authors:  T Lee Gilman; Christina M George; Melissa Vitela; Myrna Herrera-Rosales; Mohamed S Basiouny; Wouter Koek; Lynette C Daws
Journal:  Eur J Neurosci       Date:  2018-05-24       Impact factor: 3.386

Review 6.  Use of magnetic resonance imaging in pharmacogenomics.

Authors:  Roberto Viviani; Marie-Louise Lehmann; Julia C Stingl
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

7.  Interaction of antidepressant and antipsychotic drugs with the human organic cation transporters hOCT1, hOCT2 and hOCT3.

Authors:  Britta Haenisch; Eva Drescher; Lidia Thiemer; Hu Xin; Bruno Giros; Sophie Gautron; Heinz Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-18       Impact factor: 3.000

8.  Brain organic cation transporter 2 controls response and vulnerability to stress and GSK3β signaling.

Authors:  T Couroussé; A Bacq; C Belzung; B Guiard; L Balasse; F Louis; A-M Le Guisquet; A M Gardier; A H Schinkel; B Giros; S Gautron
Journal:  Mol Psychiatry       Date:  2014-08-05       Impact factor: 15.992

Review 9.  Acute tryptophan depletion in humans: a review of theoretical, practical and ethical aspects.

Authors:  Simon N Young
Journal:  J Psychiatry Neurosci       Date:  2013-09       Impact factor: 6.186

Review 10.  Treatment-resistant depression: are animal models of depression fit for purpose?

Authors:  Paul Willner; Catherine Belzung
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.